Phase 2 efficacy and pharmacodynamic study of 2-methoxyestradiol nanocrystal colloidal dispersion (Panzem NCD) in patients with taxane-refractory, metastatic, hormone-refractory prostate cancer
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs 2-methoxyestradiol (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals; EntreMed
- 24 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
- 09 Jul 2008 The expected completion date for this trial has been changed form June 2008 to Sep 2008, as reported by ClinicalTrials.gov.
- 06 Nov 2006 Status change